OVERACTIVE BLADDER THERAPEUTICS MARKET ANALYSIS

Market Challenges And Opportunities

Global Overactive Bladder Therapeutics Market: Restraints

The major restraint to the overactive bladder therapeutics market is the occurrence of unfavourable side effects associated with the prescribed drug or treatment. For instance, in 2020 an article published by the National Center for Biotechnology Information (NCBI) reported that anticholinergic drug- Oxybutynin used in the treatment of overactive bladder syndrome may cause dry mouth, dizziness and constipation as the most common side effects. Beta-3 adrenergic drug such as Mirabegron (Myrbetriq) show common adverse drug events such as hypertension, Urinary tract Infection (UTI), diarrhea, headache, dry mouth and constipation.  Also, Botox treatment poses a high risk of Urinary Tract Infections. For instance, clinical trial studies carried out by Allergan for its Botox treatment list UTI, dry eyes, painful urination and headache as the common side effects associated with the treatment. All these factors are responsible for hampering the growth of the overactive bladder therapeutics market in the forecast period. Furthermore, patent expiry of key drugs such as Detrol and Oxybutynin which are commonly prescribed for the treatment of overactive bladder syndrome can affect the market growth in a negative way. For instance, Oxybutynin patent issued to Watson Pharmaceuticals, Inc. in 2016 would expire in 2029.

Restaints